Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations

Br J Haematol. 2020 Sep;190(5):e312-e316. doi: 10.1111/bjh.16889. Epub 2020 Jun 14.

Affiliations

¹ Department of Haematology, UCL Cancer Institute, London, UK.
² Department of Haematology, University College London Hospitals NHS Foundation Trusts, London, UK.
³ HCA Healthcare, Department of Haematology, University College London NHS Foundation Trusts, London, UK.
⁴ Department of Acute Medicine, University College London Hospitals NHS Foundation Trusts, London, UK.

PMID: 32535901
DOI: 10.1111/bjh.16889

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Databases, Factual*
Female
Heart Diseases* / chemically induced
Heart Diseases* / mortality
Heart Diseases* / prevention & control
Humans
Hypertension* / chemically induced
Hypertension* / mortality
Hypertension* / prevention & control
Male
Middle Aged
Models, Cardiovascular*
Multiple Myeloma* / drug therapy
Multiple Myeloma* / mortality
Multiple Myeloma* / pathology
Oligopeptides* / administration & dosage
Oligopeptides* / adverse effects
Practice Guidelines as Topic
Retrospective Studies

Substances

Oligopeptides
carfilzomib

Grants and funding